XpressGT®
Screen for dysglycemia in routine care. Identify dysglycemia missed by fasting glucose and HbA1c — while reducing reliance on OGTT.
How It Works
XpressGT® is an enzymatic 2-hydroxybutyrate (2-HB) assay for routine clinical chemistry analyzers designed to identify clinically relevant dysglycemia beyond fasting plasma glucose and HbA1c.
Clinical validation published in Diabetes Care
Designed for routine clinical chemistry analyzers
Open for partnerships
RUO Kit available
Addressing a gap in
routine diabetes screening
Fasting plasma glucose (FPG) and HbA1c are practical screening tools, but they may miss clinically relevant postprandial dysglycemia. OGTT provides additional information, but it is time-consuming, operationally demanding and difficult to implement broadly in routine care.
A clinical validation study published in Diabetes Care evaluated 772 individuals and demonstrated that 2-HB measured with XpressGT® can identify OGTT-defined dysglycemia in individuals with normal fasting glucose and HbA1c.
Fasting Measures Miss Postprandial Dysglycemia
Up to ~40% with dysglycemia undetected
Rule-out Oriented Screening Approach
Low probability
No OGTT
Consider
OGTT
Up to ~50% fewer OGTTs in at-risk individuals
From biomarker to routine testing
Historically, broader implementation of 2-HB testing has been limited by complex analytical methods. XpressGT enables enzymatic measurement of 2-HB in serum or plasma on routine clinical chemistry analyzers.
Validated in Serum and Plasma
Agreement of XpressGT to goldstandard LC-MS was demonstrated for serum and plasma samples.
Robust & Specific
No interference from common chemically similar compounds (lactate, β- hydroxybutyrate) or blood sample defects at relevant concentration levels.
High Sample Throughput
Runs on Abbott Alinity c, Roche cobas c703, or comparable clinical analyzers. Verified repeatability (RSD < 3.5%) and intermediate precision across days and operators (RSD < 5.0%). Time to first result: 8 min.
Agreement with LC-MS Reference Method
Partner With Us
DirectSens is seeking partners to support clinical utility generation, early adoption and commercialization of XpressGT®.
Why Partner With XpressGT?
Independent clinical validation
Published in Diabetes Care.
Built for routine testing
Implementation on clinical chemistry analyzers.
Addresses a screening gap
Routine screening misses clinically relevant dysglycemia while OGTT remains difficult to scale.
Partnering Model
LDT & Early Adoption
Generate real-world evidence and evaluate implementation in routine laboratory workflows.
OEM & White Label
Integrate XpressGT into existing analyzer portfolios and diagnostic platforms.
Licensing & Co-Development
Advance XpressGT toward regulated IVD and point-of-care applications.
Partner With Us
Explore licensing, OEM, LDT and co-development opportunities for XpressGT®.
Become A Partner